Does dupilumab/dalbitux require long-term permanent injection?

Dupilumab (dupilumab) is an innovative drug used to treat immune-related diseases, especially in the treatment of atopic dermatitis (AD), asthma and chronic sinusitis with nasal polyps and other diseases. Because it regulates the immune system by inhibiting the signaling pathways of IL-4 and IL-13, many patients and doctors will question whether it requires long-term or even permanent injections.

Dupilumab, as an immunosuppressant, does often require long-term use, especially for patients who need to control chronic immune diseases. In the treatment of atopic dermatitis, the use of dupilumab is generally a long-term treatment, and the treatment cycle is usually a regular injection, with a general interval of 2 weeks or 4 weeks. This frequency of treatment helps maintain drug concentration in the body, thereby continuously suppressing the inflammatory response and achieving the effect of relieving skin symptoms.

Although the injection cycle of dupilumab is long-term, it does not mean permanent injection. Usually, as the patient's condition improves, doctors will adjust the treatment plan based on individual efficacy and side effects. In the treatment of atopic dermatitis, as skin symptoms stabilize and alleviate, some patients can gradually reduce the frequency of injections, and even in some cases, discontinue medication while maintaining stable symptoms. However, for some patients with severe or refractory disease, long-term maintenance therapy may be necessary.

The long-term efficacy of dupilumab suggests that it is a consistently effective treatment option. According to data from multiple clinical studies, dupilumab can effectively control disease activity, significantly reduce skin inflammation and itching symptoms, and reduce patients' dependence on other drugs. However, the specific time of use and whether the drug can be discontinued still need to be determined under the guidance of a doctor and based on the patient's specific condition.

Keyword tags: dupilumab, Dupilumab, long-term treatment, dabitux, atopic dermatitis, immunosuppressant, injection frequency

Reference materials：https://www.regeneron.com/downloads/dupixent_fpi.pdf